China Competitors
| SXTC Stock | USD 2.82 1.12 28.43% |
China SXT vs Nuvectis Pharma Correlation
Excellent diversification
The correlation between China SXT Pharmaceuticals and NVCT is -0.56 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding China SXT Pharmaceuticals and NVCT in the same portfolio, assuming nothing else is changed.
Moving against China Stock
| 0.79 | IPAR | Inter Parfums | PairCorr |
| 0.74 | EPC | Edgewell Personal Care Earnings Call This Week | PairCorr |
| 0.72 | NAII | Natural Alternatives | PairCorr |
| 0.7 | HLF | Herbalife Nutrition | PairCorr |
| 0.7 | 3RB | Reckitt Benckiser Split | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of China SXT's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
China SXT Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between China SXT and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of China and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of China SXT Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between China Stock performing well and China SXT Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze China SXT's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ATLN | 7.18 | 0.74 | 0.11 | 0.19 | 7.15 | 20.00 | 64.87 | |||
| IXHL | 3.85 | (0.60) | 0.00 | (0.20) | 0.00 | 10.00 | 23.38 | |||
| CYBN | 3.09 | (0.12) | 0.00 | (0.51) | 0.00 | 6.03 | 16.13 | |||
| AVR | 3.82 | 0.28 | 0.08 | 0.23 | 3.44 | 9.42 | 25.09 | |||
| SAVA | 3.94 | (0.67) | 0.00 | (0.80) | 0.00 | 9.05 | 35.02 | |||
| FATE | 3.71 | (0.35) | 0.00 | (0.14) | 0.00 | 7.27 | 20.97 | |||
| IPHA | 2.35 | (0.13) | 0.00 | (0.33) | 0.00 | 3.41 | 39.49 | |||
| MIST | 3.25 | (0.11) | 0.00 | (0.06) | 0.00 | 6.15 | 34.31 | |||
| NVCT | 2.82 | 0.36 | 0.11 | 0.31 | 2.93 | 7.20 | 17.53 |
Cross Equities Net Income Analysis
Compare China SXT Pharmaceuticals and related stocks such as Atlantic International, Incannex Healthcare, and Cybin Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATLN | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.7 M) | (2.9 M) | (2.5 M) | (1 M) | (40.8 M) | (3.2 M) | (15.3 M) | (135.5 M) | (121.9 M) | (115.8 M) |
| IXHL | (179 K) | (3.2 M) | (11 M) | (11.3 M) | (1.9 M) | (591.9 K) | (15.9 M) | (2.2 M) | (1.9 M) | (3.2 M) | (8.2 M) | (10.3 M) | (48.8 M) | (27.6 M) | (46.9 M) | (42.2 M) | (40.1 M) |
| AVR | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (17.2 M) | (30.6 M) | (46 M) | (76.3 M) | (68.7 M) | (65.2 M) |
| SAVA | (4.5 M) | (2.6 M) | (3.4 M) | 31.5 M | (12.4 M) | (14.1 M) | (14.8 M) | (11.9 M) | (6.6 M) | (4.2 M) | (6.3 M) | (31.8 M) | (72.5 M) | (97.2 M) | (24.3 M) | (21.9 M) | (23 M) |
| FATE | (13.4 M) | (13.4 M) | (14.2 M) | (20.9 M) | (25.9 M) | (30 M) | (33.5 M) | (43 M) | (66.6 M) | (98.1 M) | (173.4 M) | (212.2 M) | (255.1 M) | (160.9 M) | (186.3 M) | (167.6 M) | (159.3 M) |
| IPHA | (6.1 M) | (7 M) | (3.2 M) | (2.9 M) | (19.6 M) | (6.7 M) | 12.6 M | (48.4 M) | 3 M | (20.8 M) | (64 M) | (52.8 M) | (58.1 M) | (7.6 M) | (49.5 M) | (44.5 M) | (42.3 M) |
| MIST | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (23.2 M) | (55.2 M) | (50 M) | (42.9 M) | (57.1 M) | (59.7 M) | (41.5 M) | (37.4 M) | (39.2 M) |
| NVCT | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (12.9 M) | (18.8 M) | (22.3 M) | (19 M) | (17.1 M) | (18 M) |
China SXT Pharmaceuticals and related stocks such as Atlantic International, Incannex Healthcare, and Cybin Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in China SXT Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of China SXT Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.China SXT Competitive Analysis
The better you understand China SXT competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, China SXT's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across China SXT's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
China SXT Competition Performance Charts
Five steps to successful analysis of China SXT Competition
China SXT's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by China SXT Pharmaceuticals in relation to its competition. China SXT's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of China SXT in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact China SXT's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to China SXT Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your China SXT position
In addition to having China SXT in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gold and Gold Mining Thematic Idea Now
Gold and Gold Mining
Large and mid-size companies, ETFs and funds that are either investing, exploring or producing, gold or indirectly involved in trading or making gold products. The Gold and Gold Mining theme has 100 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold and Gold Mining Theme or any other thematic opportunities.
| View All Next | Launch |
Check out China SXT Correlation with its peers. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Will Personal Care Products sector continue expanding? Could China diversify its offerings? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every China SXT data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.426 | Earnings Share (57.15) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, China SXT's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.